Glycated peptides and methods of use
View Patent ↗The invention provides glycated peptides and glycated fragments and glycated variants thereof, antibodies and aptamers which bind thereto, compositions and kits comprising the same, related conjugates, and a database comprising data indicating the concentration of glycated peptides present in diabetic and non-diabetic persons. The invention also provides a method of monitoring glycemic control, a method of treating or preventing diabetes, a method of preventing a complication of diabetes, a method of monitoring the status of diabetes, a method of determining the efficacy of a diabetes treatment, as well as methods of detecting diabetes or a predisposition thereto.
1. A method of monitoring the glycemic control of a host, comprising
(a) measuring the concentration of a glycated peptide in the host or in a sample from the host, wherein the glycated peptide comprises (i) at least one of Peptides AA-DJ of Table 1 or (ii) an amino acid sequence selected from the group consisting of SEQ ID NOs: 24-36, and
(b) comparing the measured concentration to a control to determine whether the measured concentration in the host or sample from the host differs from the control.
2. The method of claim 1 , further comprising detecting a change in the concentration of the glycated peptide, or glycated fragment or glycated variant thereof.
3. The method of claim 1 , further comprising comparing the concentration of the glycated peptide, or glycated fragment or glycated variant thereof, to a control.
4. The method of claim 1 , wherein the concentration of the glycated peptide, or glycated fragment or glycated variant thereof, is the relative concentration of the glycated peptide, or glycated fragment or glycated variant thereof, as compared to the total concentration of both the glycated and non-glycated forms of the corresponding peptide; fragment, or variant.
5. The method of claim 1 , wherein the glycated fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-23.
6. The method of claim 1 , wherein the glycated variant comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 37-47.
7. The method of claim 1 , comprising measuring the concentration of five or more different glycated peptides, or glycated fragments or glycated variants thereof, each of which comprises (i) at least one of Peptides AA-DJ of Table 1 or (ii) an amino acid sequence selected from the group consisting of SEQ ID NOs: 24-36.
8. The method of claim 1 , wherein measuring the concentration, of the glycated peptide, or glycated fragment or glycated variant thereof, comprises contacting a sample from the host with an antibody, or conjugate comprising an antibody, that specifically binds to the glycated peptide or the glycated fragment or glycated variant thereof.
9. The method of claim 1 , wherein measuring the concentration of the glycated peptide, or glycated fragment or glycated-variant thereof, comprises contacting a sample from the host with an aptamer, or conjugate comprising an aptamer, that specifically binds to the glycated peptide, or the glycated fragment or glycated variant thereof.
10. The method of claim 1 , wherein the concentration of the glycated peptide, or glycated fragment or variant thereof, is measured in a sample of blood, blood plasma, or blood serum from the host.
11. The method of claim 1 , further comprising measuring glycated hemoglobin A1C in the host.
12. The method of claim 1 , further comprising measuring a blood glucose level of the host.
13. The method of claim 1 , wherein the method is used to prevent a complication of diabetes, detect the onset, progression, or regression of diabetes, or determine the efficacy of a diabetes treatment.
14. The method of claim 1 , wherein the method is used to detect diabetes or a predisposition to diabetes in the host, the method further comprising detecting an elevated concentration of the glycated peptide, or glycated fragment or glycated variant thereof, as compared to a control, wherein an elevation in the concentration of the glycated peptide, fragment, or variant as compared to a control is indicative of diabetes or a predisposition of diabetes in the host.